Allotera Therapeutics
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
$35MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
Provides in-network psychiatric care using AI-powered technology